Climb Bio/$CLYM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
- Ticker
- $CLYM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Wellesley Hills, United States
- Website
- climbbio.com
Climb Bio Metrics
BasicAdvanced
$628M
-
-$0.83
0.08
-
Price and volume
Market cap
$628M
Beta
0.08
52-week high
$18.33
52-week low
$1.54
Average daily volume
1.7M
Financial strength
Current ratio
31.452
Quick ratio
30.86
Long term debt to equity
0.003
Total debt to equity
0.005
Profitability
EBITDA (TTM)
-64.628
Management effectiveness
Return on assets (TTM)
-18.45%
Return on equity (TTM)
-27.10%
Valuation
Price to book
2.62
Price to tangible book (TTM)
2.62
Price to free cash flow (TTM)
-14.231
Free cash flow yield (TTM)
-7.03%
Free cash flow per share (TTM)
-0.769
Growth
Earnings per share change (TTM)
20.38%
3-year earnings per share growth (CAGR)
-21.05%
What the Analysts think about Climb Bio
Analyst ratings (Buy, Hold, Sell) for Climb Bio stock.
Analyst projections of the future price of Climb Bio stock.
Bulls say / Bears say
CLYM116 produced strong early pharmacodynamic results in 46 healthy volunteers: more than 90% free APRIL suppression and roughly 60–75% reductions in IgA, Gd-IgA1 and IgM were maintained through 12 weeks, with no serious adverse events or hypogammaglobulinaemia reported. The potential for every-12-week dosing could improve convenience if these biomarker effects translate into patients with IgA nephropathy. (Clinical Trials Arena, Climb Bio)
Budoprutug has shown an encouraging early signal in primary membranous nephropathy: all five patients in the completed Phase 1b study achieved partial or complete clinical remission by week 48, while all three evaluable patients achieved serological remission. The FDA has also granted Fast Track designation, supporting closer regulatory engagement in a disease with no approved treatment in the United States. (Climb Bio, Renal and Urology News)
Climb Bio ended the second quarter with $239.2 million in cash, cash equivalents and marketable securities after a roughly $110 million private placement. Management says this funds operations into the second half of 2028, giving the company time to advance both lead programmes towards pivotal studies without immediate dependence on another financing. (Climb Bio, Climb Bio)
The most positive budoprutug efficacy evidence comes from only five Phase 1b pMN patients, and the current Phase 2 study is open-label and enrolling about 45 people. CLYM116’s reported data are from healthy volunteers, so neither programme has yet shown that biomarker or early remission signals improve kidney outcomes in a controlled patient trial. (Climb Bio, CenterWatch)
Both assets still face substantial development and regulatory risk. Budoprutug’s key pMN, ITP and SLE data are expected in the second half or fourth quarter of 2026, while initial patient data for CLYM116’s Phase 2 study are not expected until 2027 and a Phase 3 start remains subject to further results and regulatory feedback. (Climb Bio, Clinical Trials Arena)
Climb Bio remains loss-making and may need more capital before commercial revenue. It reported a $13.5 million second-quarter loss, and its own filings warn that the cash-runway estimate depends on assumptions while further development may require substantial additional funding; a future financing could dilute shareholders. (Climb Bio, Climb Bio)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Climb Bio Financial Performance
Revenues and expenses
Climb Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Climb Bio News
AllArticlesVideos
Funds containing Climb Bio
AllEURGBP
Fund name | Fund size | $CLYM weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.